Skip to main content
SpringerLink
Log in

Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background: The mitoxantrone combination CNF and the epirubicin combination CEF have shown similar activity and less toxicity than the standard CAF combination in metastatic breast cancer (MBC). A prospective randomised study was started to compare safety and activity between CEF and CNF administered using a classical chemotherapeutic schedule in MBC.

Patients and methods: From December 1987 to June 1993, 151 patients were randomised to receive cyclophosphamide (C) 100 mg m−2 p.o. days 1–14, fluorouracil (F) 500 mg m−2 i.v. days 1 and 8, and epirubicin (E) 30 mg m−2 i.v. days 1 and 8, or mitoxantrone (N) 6 mg m−2 i.v. days 1 and 8, every 4 weeks. Seventy‐three patients were eligible for CEF and 72 for CNF.

Results: Objective responses were observed in 61.6 of the CEF group and 44.4 in CNF group (p=0.004). The median duration of response was 64 weeks in CEF and 50 weeks in CNF group (p=0.02) and median time to progression was 51 and 33 weeks, respectively (p=0.0004). At the time of analysis, all except six patients (one in CNF and five in CEF) had died and the median survival time in the CEF group was longer than in CNF (74.4 weeks vs 51.4 weeks; log-rank χ2 test p=0.015). CNF produced more hematologic toxicity than CEF (WHO scale; grades 2–4): leucopenia 84% vs 68% (p=0.03) and trombocytopenia 17% vs 4.5% (p=0.01); CEF caused more grade 2 and 3 alopecia: 93% vs 70% (p=0.00 1).

Conclusion: The combination CEF using this schedule and dosage in metastatic breast cancer is more effective with less toxicity than CNF, except for alopecia, and was associated with longer survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Smalley RV, Carpenter J, Bartolucci A, et al.: A comparison of cyclophosphamide, adriamycin, 5–fluorouracil (CAF) and cyclophosphamide, methotrexate, 5–fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. Cancer 40: 625–632, 1977

    Google Scholar 

  2. Bull JM, Tormey DC, Li S, et al.: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649–1657, 1978

    Google Scholar 

  3. Falkson G, Gelman R, Tormey DC, et al.: The Eastern Cooperative Oncology Group experience with cyclophosphamide, Adriamycin, and 5–fluorouracil (CAF) in patients with metastatic breast cancer. Cancer 56: 219–224, 1985

    Google Scholar 

  4. Brambilla C, Rossi A, Bonfante V, et al.: Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70: 261–266, 1986

    Google Scholar 

  5. Hayat M, Chauvergne J, Fargeot P, et al.: Phase III Chemotherapy comparing FAC versus FEC in advanced breast cancer: Preliminary results. Proc Am Soc Clin Oncol: C-460, 1984

  6. Intini C, Zingali G, de Micheli P, et al.: FEC versus FAC in advanced breast cancer. Results of an Italian cooperative study. Cancer Chemother Pharmacol 18 (Suppl 1): A38, 149, 1986

    Google Scholar 

  7. Bennett JM, Muss HB, Doroshow JH, et al.: A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in therapy of metastatic breast carcinoma. J Clin Oncol 6: 1611–1620, 1988

    Google Scholar 

  8. Henderson IC, Wolff S, Allegra J, et al.: Mitoxantrone versus doxorubicin in advanced breast cancer: a randomized trial in 220 patients. Third European Conference on Clinical Oncology and Cancer Nursing. ECCO 3. Novantrone Satellite Symposium. Stockholm, 19 June, 1985, Abstract Book, 4

  9. Neidhart JA, Gochnour D, Roach R, et al.: A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4: 672–677, 1986

    Google Scholar 

  10. Alexander J, Daimak N, Berber HJ, et al.: Serial assessement of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300: 278–283, 1979

    Google Scholar 

  11. Miller AB, Hoogstraten B, Staquet M, et al.: Reporting results of cancer treatment. Cancer 47: 207–214, 1981

    Google Scholar 

  12. Hayward JL, Carbone PP, Heuson JC, et al.: Assessment of response to therapy in advanced breast cancer. Eur J Cancer Cli Oncol 13: 89–94, 1977

    Google Scholar 

  13. Cochran WG: The chi-square test of goodness of fit. Ann Math Stat 23: 315–345, 1952

    Google Scholar 

  14. Winer BJ: Statistical Principles in Experimental Design. McGraw-Hill, London, England, 1970

    Google Scholar 

  15. Mehta CR, Patel NR: A network algorithm for performing Fisher's exact test in r x c contingency tables. J Am Stat Assoc 78: 427–434, 1983

    Google Scholar 

  16. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958

    Google Scholar 

  17. Peto R, Pike MC: Conservation of the approximation 6.O-E/2/E in the log-rank test for survival data or tumor incidence data. Biometrics 29: 579–584, 1973

    Google Scholar 

  18. Allegra JC, Woodcock T, Woolf S, et al.: A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer. Invest New Drugs 3: 153–161, 1985

    Google Scholar 

  19. Henderson IC, Allegra JC, Woodcock T, et al.: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560–571, 1989

    Google Scholar 

  20. Cowan JD, Neidhart J, McClude S, et al.: Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst 83: 1077–1084, 1991

    Google Scholar 

  21. Lawton PA, Spittle MF, Ostrowski MJ, et al.: A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma. Clin Oncol (R. Coll Radiol) 5(2): 80–84, 1993

    Google Scholar 

  22. Follezou JY, Palangie T, Feuilhade F, et al.: Essai randomise comparant la mitoxantrone a l'adriamycine dans les cancers du sein evolves. La presse medicale 16(16): 765–768, 1987

    Google Scholar 

  23. Periti P, Pannuti F, Della Cuna GR, et al.: Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast cancer. Cancer Invest 9: 249–255, 1991

    Google Scholar 

  24. Taguchi T, Sakai K, Terasawa T, et al.: Result of clinical trials with a CAF (cyclophosphamide, adriamycin, and 5–fluorouracil) regimen versus a CMITF (cyclophosphamide, mitoxantrone and 5–fluorouracil) regimen in advanced relapsed breast cancer. Jpn J Cancer Chemother 13: 2820–2828 1986

    Google Scholar 

  25. Buyukunal E, Derman U, Serdengecti S, et al.: A clinical trial of mitoxantrone versus doxorubicin in combination chemotherapy for metastatic breast cancer. Chemioterapia 6: 377–379, 1987

    Google Scholar 

  26. Heidemann E, Steinke B, Hartlapp J, et al.: Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. Onkologie 13:24–27, 1990

    Google Scholar 

  27. Alonso MC, Tabernero JM, Ojeda B, et al.: A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5–fluorouracil versus cyclophosphamide, adriamycin, and 5–fluorouracil in patients with metastatic breast cancer. Breast Cancer Res Treat 34: 15–24, 1995

    Google Scholar 

  28. Stewart DJ, Evans WK, Shepherd FA, et al.: Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. J Clin Oncol 15: 1897–1905, 1997

    Google Scholar 

  29. Hausmaninger H, Lehnert M, Steger G, et al.: Vindesineepirubicin versus vindesine-mitoxantrone in metastatic breast cancer. Onkologie 12: 225–229, 1989

    Google Scholar 

  30. Rahman ZU, Frye DK, Smith TL, et al.: Results and long term followup for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer 85: 104–111, 1999

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Emilio Esteban, Servicio de Oncología Médica, Hospital Central de Asturias, Oviedo, Spain

    E. Esteban, A.J. Lacave, J.L. Fernández, N. Corral, J.M. Buesa, E. Estrada, I. Palacio, J.M. Vieitez, I. Muñiz & E. Alvarez

Authors
  1. E. Esteban
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A.J. Lacave
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J.L. Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Corral
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J.M. Buesa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Estrada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. Palacio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J.M. Vieitez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. I. Muñiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E. Alvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Esteban, E., Lacave, A., Fernández, J. et al. Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. Breast Cancer Res Treat 58, 141–150 (1999). https://doi.org/10.1023/A:1006387801960

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006387801960

Search

Navigation